Ritanserin blocks Ca
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
/ metabolism
Animals
Arteries
/ cytology
Binding Sites
Calcium Channels, L-Type
/ chemistry
Electrophysiological Phenomena
/ drug effects
Ketanserin
/ metabolism
Male
Molecular Docking Simulation
Muscle, Smooth, Vascular
/ cytology
Myocytes, Smooth Muscle
/ drug effects
Protein Binding
Rats, Wistar
Ritanserin
/ metabolism
Serotonin 5-HT2 Receptor Antagonists
/ metabolism
Vasoconstriction
/ drug effects
5-HT2 receptor
CaV1.2 channel
Raynaud’s syndrome
docking simulation
homology modeling
ritanserin
Journal
Acta pharmacologica Sinica
ISSN: 1745-7254
Titre abrégé: Acta Pharmacol Sin
Pays: United States
ID NLM: 100956087
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
17
10
2019
accepted:
19
01
2020
pubmed:
7
3
2020
medline:
2
6
2021
entrez:
6
3
2020
Statut:
ppublish
Résumé
Ca
Identifiants
pubmed: 32132658
doi: 10.1038/s41401-020-0370-1
pii: 10.1038/s41401-020-0370-1
pmc: PMC7608335
doi:
Substances chimiques
Cacna1c protein, rat
0
Calcium Channels, L-Type
0
Serotonin 5-HT2 Receptor Antagonists
0
Ritanserin
145TFV465S
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
71145-03-4
Ketanserin
97F9DE4CT4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1158-1166Références
Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM. Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 1985;27:600–11.
pubmed: 2860558
https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=97 . Accessed 9 Mar 2019.
Kriston L, von Wolff A, Westphal A, Hölzel LP, Härter M. Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety 2014;31:621–30.
pubmed: 24448972
Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis [published correction appears in Br J Psychiatry. 2011;198:159]. Br J Psychiatry. 2010;197:174–9.
pubmed: 20807960
Cornish JW, Maany I, Fudala PJ, Ehrman RN, Robbins SJ, O’Brien CP. A randomized, double-blind, placebo-controlled study of ritanserin pharmacotherapy for cocaine dependence. Drug Alcohol Depend. 2001;61:183–9.
pubmed: 11137283
Wu K, Hunter TL, Proakis AG. Effects of ritanserin on transmembrane action potentials in canine purkinje fibres. Proc Soc Exp Biol Med. 1992;199:88–92.
pubmed: 1728042
Boroda S, Niccum M, Raje V, Purow BV, Harris TE. Dual activities of ritanserin and R59022 as DGKa inhibitors and serotonin receptor antagonists. Biochem Pharmacol. 2017;123:29–39.
pubmed: 27974147
Arranz-Nicolás J, Ogando J, Soutar D, Arcos-Pérez R, Meraviglia-Crivelli D, Mañes S, et al. Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals. Cancer Immunol Immunother. 2018;67:965–98.
pubmed: 29572701
Olmez I, Love S, Xiao A, Manigat L, Randolph P, McKenna BD, et al. Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol. 2018;20:192–202.
pubmed: 29048560
Franks CE, Campbell ST, Purow BW, Harris TE, Hsu KL. The ligand binding landscape of diacylglycerol kinases. Cell Chem Biol. 2017;24:870–80.
pubmed: 28712745
pmcid: 5551460
Campbell ST, Franks CE, Borne AL, Shin M, Zhang L, Hsu KL. Chemoproteomic discovery of a ritanserin-targeted kinase network mediating apoptotic cell death of lung tumor cells. Mol Pharmacol. 2018;94:1246–55.
pubmed: 30158316
pmcid: 6160665
Van Nueten JM, Schuurkes JAJ, De Ridder WJE, Kuyps JJMD, Janssens WJ. Comparative pharmacological profile of ritanserin and ketanserin. Drug Dev Res. 1986;8:187–95.
Frenken M, Kaumann AJ. Allosteric properties of the 5-HT
pubmed: 3110629
Conolan S, Quinn MJ, Taylor DA. In vivo and in vitro activity of selective 5-hydroxytryptamine
pubmed: 3801767
pmcid: 1917053
Okoro EO, Marwood JF, Stokes GS. The interaction between Ca
pubmed: 7596129
Okoro EO, Marwood JF. Effects of 5-HT
pubmed: 9043803
Okoro EO. Overlap in the pharmacology of L-type Ca
pubmed: 10504036
Kumagai S, Morinobu A, Ozaki S, Nakao K, Ishida H. Sarpogrelate hydrochloride for Raynaud’s phenomenon of patients with collagen diseases. Ryumachi. 1998;38:504–10.
pubmed: 9721558
Yoshimasu T, Ikeda T, Uede K, Kanazawa N, Furukawa F. Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis. J Dermatol. 2012;39:536–40.
pubmed: 22077618
Ogawa T, Ogura T, Hirata A, Hayashi N, Izumi Y, Morita S, et al. Sarpogrelate hydrochloride therapy for Raynaud’s phenomenon in patients with systemic sclerosis. Int J Rheum Dis. 2008;11:A483.
Rirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong Ghogomu E, Wells GA, et al. Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2017;12:CD000467.
pubmed: 29237099
Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev. 2015;67:821–70.
pubmed: 26362469
pmcid: 4630564
Fusi F, Cavalli M, Mulholland D, Crouch NR, Coombes P, Dawson G, et al. Cardamonin is a bifunctional vasodilator that inhibits Ca
pubmed: 19923439
Mugnai P, Durante M, Sgaragli G, Saponara S, Paliuri G, Bova S, et al. L-type Ca
Fusi F, Sgaragli G, Saponara S. Mechanism of myricetin stimulation of vascular L-type Ca
pubmed: 15665142
Petkov GV, Fusi F, Saponara S, Gagov H, Sgaragli GP, Boev KK. Characterization of voltage-gated calcium currents in freshly isolated smooth muscle cells from rat tail main artery. Acta Physiol Scand. 2001;173:257–65.
pubmed: 11736688
Karmažínová M, Lacinová Ľ. Measurement of cellular excitability by whole cell patch clamp technique. Physiol Res. 2010;59:S1–7.
pubmed: 20626213
Altura BM, Altura BT, Carella A, Turlapaty PD. Adverse effects of artificial buffers on contractile responses of arterial and venous smooth muscle. Br J Pharmacol. 1980;69:207–14.
pubmed: 6254589
pmcid: 2044261
Bova S, Trevisi L, Debetto P, Cima L, Furnari M, Luciani S, et al. Vasorelaxant properties of norbormide, a selective vasoconstrictor agent for the rat microvasculature. Br J Pharmacol. 1996;117:1041–6.
pubmed: 8882594
pmcid: 1909795
Magnon M, Calderone V, Floch A, Cavero I. Influence of depolarization on vasorelaxant potency and efficacy of Ca
Fusi F, Manetti F, Durante M, Sgaragli G, Saponara S. The vasodilator papaverine stimulates L-type Ca
Koebel MR, Schmadeke G, Posner RG, Sirimulla S. AutoDock VinaXB: implementation of XBSF, new empirical halogen bond scoring function, into AutoDock Vina. J Cheminform. 2016;8:27.
pubmed: 27195023
pmcid: 4870740
Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202–13.
pubmed: 26400175
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;16:2785–91.
Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein–ligand interaction profiler. Nucleic Acids Res. 2015;43:W443–7.
pubmed: 25873628
pmcid: 4489249
Bean BP, Cohen CJ, Tsien RW. Lidocaine block of cardiac sodium channels. J Gen Physiol. 1983;81:613–42.
pubmed: 6306139
pmcid: 2216565
Ives HE, Schultz GS, Galardy RE, Jamieson JD. Preparation of functional smooth muscle cells from the rabbit aorta. J Exp Med. 1978;148:1400–13.
pubmed: 214509
Saponara S, Durante M, Spiga O, Mugnai P, Sgaragli G, Huong TT, et al. Functional, electrophysiological and molecular docking analysis of the modulation of Ca
pubmed: 26493241
Hockerman GH, Peterson BZ, Johnson BD, Catterall WA. Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361–96.
pubmed: 9131258
Saponara S, Sgaragli G, Fusi F. Quercetin as a novel activator of L-type Ca
pubmed: 11934824
pmcid: 1573296
Kuriyama H, Kitamura K, Nabata H. Pharmacological and physiological significance of ion channels and factors that modulate them in vascular tissues. Pharmacol Rev. 1995;47:387–573.
pubmed: 8539268
McDonald TF, Pelzer S, Trautwein W, Pelzer DJ. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev. 1994;74:365–507.
pubmed: 8171118
Bean BP. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc Natl Acad Sci U S A. 1984;81:6388–92.
pubmed: 6093100
pmcid: 391929
Fransen P, Van Hove CE, van Langen J, Schrijvers DM, Martinet W, De Meyer GR, et al. Contribution of transient and sustained calcium influx, and sensitization to depolarization-induced contractions of the intact mouse aorta. BMC Physiol. 2012;12:9.
pubmed: 22943445
pmcid: 3499395
Tang L, Gamal El-Din TM, Swanson TM, Pryde DC, Scheuer T, Zheng N, et al. Structural basis for inhibition of a voltage-gated Ca
pubmed: 27556947
pmcid: 5161592
Tikhonov DB, Zhorov BS. Structural model for dihydropyridine binding to L-type calcium channels. J Biol Chem. 2009;284:19006–17.
pubmed: 19416978
pmcid: 2707233
Trezza A, Bernini A, Spiga O. Identification of “on-off residues” in rat Ca
Fusi F, Trezza A, Spiga O, Sgaragli G, Bova S. Ca(v)1.2 channel current block by the PKA inhibitor H-89 in rat tail artery myocytes via a PKA-independent mechanism: electrophysiological, functional, and molecular docking studies. Biochem Pharmacol. 2017;140:53–63.
pubmed: 28583845
Fusi F, Saponara S, Sgaragli G, Cargnelli G, Bova S. Ca
pubmed: 12237251
pmcid: 1573499
Ratz PH, Berg KM, Urban NH, Miner AS. Regulation of smooth muscle calcium sensitivity: KCl as a calcium sensitizing stimulus. Am J Physiol Cell Physiol. 2005;288:C769–83.
pubmed: 15761211
Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Ketanserin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;2:CD000954.